Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowed)
ID: 353244Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353244

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-008.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Strategies for Controlled Release of HIV Vaccines (SCORE-H)" under the R01 Research Project Grant mechanism. This initiative aims to support innovative research focused on developing controlled-release vaccine strategies to enhance immune responses for HIV prevention, treatment, and potential cure, with an emphasis on simplified or single-shot vaccination formulations. The NIH is particularly interested in projects that demonstrate proof-of-principle, optimize approaches in animal models, and evaluate safety and efficacy in vaccine delivery, requiring applicants to form cross-disciplinary teams and include measurable timelines and milestones in their proposals. A total of $3.3 million is allocated for funding, with an expectation of 3-5 awards, and applications are due by July 30, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-008-Full-Announcement.html
    RFA-AI-24-008.html
    The National Institutes of Health (NIH) is issuing a new funding opportunity titled "Strategies for Controlled Release of HIV Vaccines" (SCORE-H) under the R01 Research Project Grant mechanism to advance research on controlled-release strategies for HIV vaccines. The aim is to develop innovative solutions that enhance immune responses for HIV prevention, treatment, and potential cure through improved vaccination formulations, including single-shot options. The NIH is particularly interested in projects that demonstrate proof-of-principle, optimize approaches in animal models, and evaluate safety and efficacy in vaccine delivery. Applicants must form cross-disciplinary teams and include measurable timelines and milestones in their proposals, emphasizing the importance of collaboration and behavioral research in product development. A total of $3.3 million is allocated for funding, with an anticipation of 3-5 awards. Eligible applicants include higher education institutions, nonprofits, and for-profit organizations. The application process requires adherence to strict guidelines, with submissions due by July 31, 2024. This initiative underscores NIH's commitment to addressing the ongoing challenge of HIV through innovative vaccine research and development.
    Similar Opportunities
    Engineering Durable HIV Vaccine Responses (ENDURE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Engineering Durable HIV Vaccine Responses (ENDURE)" to support research aimed at enhancing immune responses to HIV vaccines. This initiative, announced by the National Institute of Allergy and Infectious Diseases (NIAID), seeks to fund basic and applied research that elucidates factors contributing to durable immune responses, with a focus on innovative vaccine design and administration methods. The NIH plans to allocate up to $3 million for 2-4 grants in fiscal year 2025, with applications encouraged from a diverse range of organizations, including educational institutions and community-based organizations. Interested applicants should note that the application deadline is October 9, 2024, and are encouraged to submit a letter of intent to facilitate the review process; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "HIV Vaccine Research and Design (HIVRAD) Program," aimed at advancing research for an effective prophylactic vaccine against HIV/AIDS. This grant encourages multi-disciplinary projects that address significant scientific questions in vaccine discovery, including preclinical evaluations in non-human primate models, while explicitly prohibiting clinical trials. The NIH plans to fund 1-2 awards totaling approximately $5 million for fiscal year 2025, with applications due by March 13, 2024, and an open submission date starting February 13, 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the detailed application guidelines available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-037.html.
    Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Strategies for Eliminating HIV Proteins (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research to develop molecules that target HIV proteins or RNA for degradation. The initiative encourages applications focusing on novel therapeutic methods rather than traditional drug discovery approaches, with a total funding amount of $1.2 million anticipated for one to two awards in fiscal year 2025. This opportunity is particularly significant as it seeks to advance research that could overcome existing limitations in HIV treatment methodologies, fostering diverse applicant eligibility from various institutions and organizations, including historically underrepresented groups. Interested applicants must submit their proposals by December 5, 2024, and can find additional information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD), aimed at advancing HIV-1 vaccine candidates from preclinical studies to clinical trial readiness. This program supports a range of activities including immunogenicity studies, manufacturing processes, and regulatory compliance, with a focus on innovative vaccine technologies that can elicit broadly neutralizing antibodies. The funding opportunity is significant in addressing ongoing health challenges related to the HIV/AIDS epidemic, with an award ceiling of $3 million and applications due by March 14, 2025. Interested applicants can find more information and submission details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Mechanisms of Inducing HIV Immunity in Early Life" (MIEL) under grant number RFA-AI-24-029. This initiative aims to support basic and applied research focused on understanding how immunity to HIV can be developed and maintained in children from birth to under 12 years old, particularly through the study of prophylactic vaccinations and broadly neutralizing antibodies (bNAbs). The NIH plans to commit $3 million for FY 2025 to fund 3-4 awards, with individual budgets not exceeding $750,000 per year. Applications are due by October 10, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity aimed at exploring innovative HIV cure strategies at the initiation of combination antiretroviral therapy (cART). This initiative seeks to identify and develop interventions that can be applied at the start of cART or following treatment interruptions, with the ultimate goal of achieving sustained treatment-free remission. The funding, available for up to two years with a maximum budget of $275,000, is open to a diverse range of eligible applicants, including higher education institutions, non-profits, and for-profit entities. Interested parties can find more information and application guidelines at the NIH grants website, with a submission deadline set for September 7, 2026.
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies that can be implemented at the onset of combination antiretroviral therapy (cART) or upon restarting cART after an analytical treatment interruption, with the ultimate goal of achieving sustained treatment-free remission. The NIH encourages multidisciplinary research approaches that enhance understanding of HIV dynamics and improve strategies for sustained remission, while excluding clinical trials. Interested applicants, including a diverse range of institutions such as historically black colleges, tribal governments, and community-based organizations, must submit their proposals by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive methods for HIV and associated complications. The primary objective of this grant is to facilitate the planning activities necessary for submitting an Investigational New Drug (IND) application to the FDA, with a focus on translating innovative research into effective drug products. This funding opportunity is particularly significant as it encourages collaboration among multidisciplinary teams to address critical health challenges related to HIV. Interested applicants can apply starting February 13, 2024, with a total funding amount of $1,000,000 anticipated for 2-3 awards in fiscal year 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-029.html.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the neuroimmune connections related to HIV and substance use disorders. This initiative seeks to identify and characterize neuroimmune networks and communication pathways, as well as discover novel modulatory tools that can enhance understanding of the regulatory mechanisms contributing to the comorbidity of HIV and substance use disorders. The NIH intends to allocate up to $2 million to fund approximately six awards, with individual budgets not exceeding $275,000 over a two-year period. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.